Biological researchers face an explosion of data arising from human genome projects and recent high throughput experiments. There are many traditional techniques for analyzing data, including ...

A. Keith Stewart, MB, ChB: Outcomes for multiple myeloma patients have improved dramatically over the past decade. This has come about as the result of the introduction of a whole new class of novel ...

A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer. Background: Multiple cancers have been treated successfully ...

Regeneron Pharmaceuticals announced initial results from the Phase 1b LINKER-MM2 trial evaluating linvoseltamab, used in combination with carfilzomib or bortezomib, for patients with ...

Combination therapies in multiple myeloma show superior efficacy over monotherapies, with higher response rates and progression-free survival. Monotherapy with agents like Empliciti and Darzalex shows ...

In order to preserve first-line drugs for treating malaria, multiple combination therapies should be deployed within a population to prevent resistance from developing, according to Maciej Boni from ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% ...

Please provide your email address to receive an email when new articles are posted on . Patients had a reduced risk for disease progression or death when treated with daratumumab-lenalidomide vs.